Company News
Evommune Shares Fall 27% After AD Trial
Evommune Inc's shares plunged 27% in after‑hours trading following failure of its EVO756 Phase 2b atopic dermatitis trial.
The double‑blind, placebo‑controlled study of 121 adults did not meet the pri
